top of page


OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion
OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties.

nuaxia
1 day ago2 min read


Novartis terminates BioArctic BrainTransporter neuroscience collaboration after discontinuing antibody programme
Novartis has terminated its neuroscience collaboration with BioArctic following discontinuation of the underlying antibody programme, ending a BrainTransporter licensing arrangement established in August 2025.

nuaxia
Nov 42 min read


Astellas signs option and licensing agreement with Audax Biosciences worth up to $1.34bn for cancer therapy DAX-044
Astellas secures an exclusive global option to license Audax Biosciences' investigational IL-12 fusion therapy DAX-044

nuaxia
Oct 292 min read


Biocon expands Yesintek biosimilar licensing rights to nine additional international markets
Biocon has secured additional licensing rights for its Yesintek ustekinumab biosimilar across nine international markets, broadening its planned commercial footprint.

nuaxia
Oct 272 min read


Celltrion licenses Kaigene anti-APRIL antibody KG013 for up to $580.5 million
Celltrion has licensed Kaigene's next-generation anti-APRIL antibody KG013 in a global agreement worth up to $580.5 million plus royalties.

nuaxia
Oct 232 min read


Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion
Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion.

nuaxia
Oct 232 min read


Astellas signs AI Proteins miniprotein therapeutics collaboration valued at more than $400 million
Astellas Pharma and AI Proteins have signed a research and licensing agreement worth more than $400 million in potential value to develop novel miniprotein therapeutics.

nuaxia
Oct 222 min read


Roche signs Hansoh Pharma oncology ADC collaboration with more than $15 billion in potential milestones
Roche and Hansoh Pharma have signed a major oncology licensing agreement involving antibody-drug conjugates, with more than $15 billion in potential milestone payments.

nuaxia
Oct 202 min read


AstraZeneca signs $1.5 billion AI drug discovery collaboration with insitro for cardiometabolic diseases
AstraZeneca and insitro have entered a $1.5 billion AI-enabled drug discovery collaboration targeting difficult-to-treat cardiometabolic diseases.

nuaxia
Oct 162 min read


Transcenta and WuXi Biologics sign HiCB technology licensing and strategic collaboration
Transcenta Therapeutics and WuXi Biologics have entered a strategic licensing collaboration covering Transcenta's HiCB continuous bioprocessing technologies and ExcelPro media platform.

nuaxia
Sep 101 min read
bottom of page